INTRODUCTION: Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a highly aggressive neoplasm which prevalently affects children and is characterized by a severe prognosis. CASE PRESENTATION: The authors describe an extremely rare case of a primary spinal AT/RT that occurred in a young girl. The patient underwent a wide surgical resection of a lumbar mass, followed by aggressive chemotherapy, myeloablative treatment, and local radiotherapy. After 7 months from the end of the treatment, the patient experienced local recurrence and was treated with surgery and second-line chemotherapy with antiangiogenic purposes, consisting of oral vinorelbine, cyclophosphamide, and celecoxib. Treatment was well tolerated, and patient was still alive 36 months after diagnosis. CONCLUSION: The peculiarity of this case report is the clinical-radiological response to a metronomic therapy in a case of early-relapsing spinal AT/RT despite previous maximal surgery, chemotherapy, and radiotherapy.
INTRODUCTION: Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a highly aggressive neoplasm which prevalently affects children and is characterized by a severe prognosis. CASE PRESENTATION: The authors describe an extremely rare case of a primary spinal AT/RT that occurred in a young girl. The patient underwent a wide surgical resection of a lumbar mass, followed by aggressive chemotherapy, myeloablative treatment, and local radiotherapy. After 7 months from the end of the treatment, the patient experienced local recurrence and was treated with surgery and second-line chemotherapy with antiangiogenic purposes, consisting of oral vinorelbine, cyclophosphamide, and celecoxib. Treatment was well tolerated, and patient was still alive 36 months after diagnosis. CONCLUSION: The peculiarity of this case report is the clinical-radiological response to a metronomic therapy in a case of early-relapsing spinal AT/RT despite previous maximal surgery, chemotherapy, and radiotherapy.
Authors: M Benesch; K Bartelheim; G Fleischhack; B Gruhn; P G Schlegel; O Witt; K D Stachel; H Hauch; C Urban; F Quehenberger; M Massimino; T Pietsch; M Hasselblatt; F Giangaspero; U Kordes; R Schneppenheim; P Hauser; T Klingebiel; M C Frühwald Journal: Bone Marrow Transplant Date: 2014-01-13 Impact factor: 5.483
Authors: Tanya M Tekautz; Christine E Fuller; Susan Blaney; Maryam Fouladi; Alberto Broniscer; Thomas E Merchant; Matthew Krasin; James Dalton; Gregory Hale; Larry E Kun; Dana Wallace; Richard J Gilbertson; Amar Gajjar Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: Irene Slavc; Monika Chocholous; Ulrike Leiss; Christine Haberler; Andreas Peyrl; Amedeo A Azizi; Karin Dieckmann; Adelheid Woehrer; Christina Peters; Georg Widhalm; Christian Dorfer; Thomas Czech Journal: Cancer Med Date: 2013-12-11 Impact factor: 4.452
Authors: Adam W Studebaker; Brian J Hutzen; Christopher R Pierson; Kellie B Haworth; Timothy P Cripe; Eric M Jackson; Jeffrey R Leonard Journal: Mol Ther Oncolytics Date: 2017-05-25 Impact factor: 7.200